Newlink Genetics Corporation Share Price (NASDAQ: LUMO)

▲

-4.34

(-100%)

Last updated on December 11, 2024 at 12:00 am IST

$₹

The stock has been delisted from the stock exchange on 11 Dec 2024

Check the interactive Newlink Genetics Corporation Stock chart to analyse performance

Newlink Genetics Corporation Key Stats

Check Newlink Genetics Corporation key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$4.34
Open	$4.33
Market Capitalization	$37.5M
Today's Volume	$390.9K
Revenue TTM	$2.2M
EBITDA	$-36.3M
Earnings Per Share (EPS)	$-4.28
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-172.83%

Global Institutional Holdings in Newlink Genetics Corporation

Name
Holdings %
Name
Holdings %
Private Advisor Group, LLC
8.61%
Goldman Sachs Group Inc
4.19%
Vanguard Group Inc
2.82%
Renaissance Technologies Corp
2.47%
Jefferies Financial Group Inc
1.40%
Greenwich Wealth Management LLC
0.88%

Analyst Recommendation on Newlink Genetics Corporation Stock

Rating

Trend

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Newlink Genetics Corporation(by analysts ranked 0 to 5 stars)

Newlink Genetics Corporation Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY18

FY19

FY20

FY21

FY22

FY23

	FY18	Y/Y Change
Revenue	$1.2M	↑ 209.23%
Net Income	$-53.6M	↓ 25.51%
Net Profit Margin	-4.4K%	↑ 14004.94%

	FY19	Y/Y Change
Revenue	$936.0K	↓ 22.39%
Net Income	$-43.0M	↓ 19.79%
Net Profit Margin	-4.6K%	↓ 148.81%

	FY20	Y/Y Change
Revenue	$168.0K	↓ 82.05%
Net Income	$-5.7M	↓ 86.83%
Net Profit Margin	-3.4K%	↑ 1222.01%

	FY21	Y/Y Change
Revenue	$230.0K	↑ 36.9%
Net Income	$-30.4M	↑ 437.35%
Net Profit Margin	-13.2K%	↓ 9859.6%

	FY22	Y/Y Change
Revenue	$1.5M	↑ 562.17%
Net Income	$-31.1M	↑ 2.08%
Net Profit Margin	-2.0K%	↑ 11190.9%

	FY23	Y/Y Change
Revenue	$2.1M	↑ 34.67%
Net Income	$-34.0M	↑ 9.57%
Net Profit Margin	-1.7K%	↑ 380.14%

Q2 FY23

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

	Q2 FY23	Q/Q Change
Revenue	$527.0K	↓ 23.73%
Net Income	$-8.9M	↑ 34.16%
Net Profit Margin	-1.7K%	↓ 731.3%

	Q3 FY23	Q/Q Change
Revenue	$7.0K	↓ 98.67%
Net Income	$-8.3M	↓ 7.07%
Net Profit Margin	-118.6K%	↓ 116876.74%

	Q4 FY23	Q/Q Change
Revenue	$826.0K	↑ 11700.0%
Net Income	$-9.5M	↑ 13.94%
Net Profit Margin	-1.1K%	↑ 117426.51%

	Q1 FY24	Q/Q Change
Revenue	$165.0K	↓ 80.02%
Net Income	$-10.4M	↑ 10.4%
Net Profit Margin	-6.3K%	↓ 5182.96%

	Q2 FY24	Q/Q Change
Revenue	$488.0K	↑ 195.76%
Net Income	$-7.6M	↓ 27.68%
Net Profit Margin	-1.5K%	↑ 4780.54%

	Q3 FY24	Q/Q Change
Revenue	$726.0K	↑ 48.77%
Net Income	$-7.5M	↓ 1.11%
Net Profit Margin	-1.0K%	↑ 518.83%

FY18

FY19

FY20

FY21

FY22

FY23

	FY18	Y/Y Change
Profit	$12.5M	↑ 3098.46%

	FY19	Y/Y Change
Profit	$899.0K	↓ 92.79%

	FY20	Y/Y Change
Profit	$168.0K	↓ 81.31%

	FY21	Y/Y Change
Profit	$230.0K	↑ 36.9%

	FY22	Y/Y Change
Profit	$1.5M	↑ 562.17%

	FY23	Y/Y Change
Profit	$2.1M	↑ 34.67%

Q2 FY23

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

	Q2 FY23	Q/Q Change
Profit	$518.0K	↓ 24.05%

	Q3 FY23	Q/Q Change
Profit	$-1000.0	↓ 100.19%

	Q4 FY23	Q/Q Change
Profit	$808.0K	↓ 80900.0%

	Q1 FY24	Q/Q Change
Profit	$163.0K	↓ 79.83%

	Q2 FY24	Q/Q Change
Profit	$486.0K	↑ 198.16%

	Q3 FY24	Q/Q Change
Profit	$726.0K	↑ 49.38%

FY18

FY19

FY20

FY21

FY22

	FY18	Y/Y Change
Operating Cash Flow	$-37.9M	↓ 21.42%
Investing Cash Flow	$117.0K	↓ 44.55%
Financing Cash Flow	$-148.0K	↓ 100.2%

	FY19	Y/Y Change
Operating Cash Flow	$-30.2M	↓ 20.38%
Investing Cash Flow	$77.0K	↓ 34.19%
Financing Cash Flow	$-59.0K	↓ 60.14%

	FY20	Y/Y Change
Operating Cash Flow	$-23.0M	↓ 23.87%
Investing Cash Flow	$116.6M	↑ 151392.21%
Financing Cash Flow	$75.0K	↓ 227.12%

	FY21	Y/Y Change
Operating Cash Flow	$-29.6M	↑ 28.92%
Investing Cash Flow	$26.0M	↓ 77.74%
Financing Cash Flow	$-192.0K	↓ 356.0%

	FY22	Y/Y Change
Operating Cash Flow	$-26.6M	↓ 10.2%
Investing Cash Flow	$-11.4M	↓ 143.74%
Financing Cash Flow	$-821.0K	↑ 327.6%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.7M	↓ 27.31%
Investing Cash Flow	$1.1M	↑ 0.0%
Financing Cash Flow	$-574.0K	↑ 85.76%

About Newlink Genetics Corporation

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private.

Organization	Newlink Genetics Corporation
Employees	30
CEO	Mr. Richard J. Hawkins
Industry	Health Technology

Key Management of Newlink Genetics Corporation

Name	Title
Mr. Richard J. Hawkins	Founder, CEO & Chairman
Dr. John C. McKew Ph.D.	Chief Scientific Officer & President
Ms. Lori D. Lawley CPA	CFO & Principal Accounting Officer
Ms. Lisa Wells Miller	Senior Director of Investor Relations
Mr. Bradley J. Powers J.D.	Chief Compliance Officer & General Counsel
Mr. Aaron Schuchart B.B.A., CPA, M.B.A.	Chief Business Officer
Dr. Pisit Pitukcheewanont FAAP, M.D.	Chief Medical Officer
Ms. Alpa Parikh	Senior Vice President of CMC & Supply Management
Mr. Eddie L. Varnado M.B.A.	Corporate Controller

Important FAQs about investing in LUMO Stock from India :

What is Newlink Genetics Corporation share price today?

Newlink Genetics Corporation share price today is as on December 11, 2024 at 12:00 am IST at the close of the market. Newlink Genetics Corporation share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Newlink Genetics Corporation share?

Newlink Genetics Corporation share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Newlink Genetics Corporation stock price today i.e. December 11, 2024 at 12:00 am IST is closed at , lower by 100% versus the 52 week high.

How to invest in Newlink Genetics Corporation Stock (LUMO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Newlink Genetics Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Newlink Genetics Corporation Shares .

What is the minimum amount required to buy Newlink Genetics Corporation Stock (LUMO) from India?

Indian investors can start investing in Newlink Genetics Corporation (LUMO) shares with as little as ₹87.7613 or $1 (as of September 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹877.61 in Newlink Genetics Corporation stock (as per the Rupee-Dollar exchange rate as on September 18, 2025). Learn more about fractional shares .

What are the returns that Newlink Genetics Corporation has given to Indian investors in the last 5 years?

Newlink Genetics Corporation stock has given 0.0% share price returns and 19.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Sim Acquisition Corp I-a
$0.24
-7.69%
Dakota Gold Corp
$4.49
+0.22%
Helmerich & Payne, Inc.
$20.89
-4.04%
Allison Transmission Holdings, Inc.
$87.33
-0.4%
Unlimited Hfeq Equity Ls Etf
$21.77
-0.5%
Spdr Msci World Strategicfac
$139.83
+0.39%
Barfresh Food Group Inc
$3.09
+6.92%
Ishares Large Cap Max Buffer Mar Etf
$26.10
+0.12%
Bok Financial Corporation
$110.12
+0.92%

Explore all